Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

18 June 2015: Clinical Research  

Assessment of Macular Peripapillary Nerve Fiber Layer and Choroidal Thickness Changes in Pregnant Women with Gestational Diabetes Mellitus, Healthy Pregnant Women, and Healthy Non-Pregnant Women

Gokhan Acmaz ABE , Mustafa Atas ABCE , Ahmet Gulhan ABDE , Banu Acmaz ABE , Fatma Atas ABC , Huseyin Aksoy EF , Gokmen Zararsiz CD , Gokcen Gokce F

DOI: 10.12659/MSM.893221

Med Sci Monit 2015; 21:1759-1764

0 Comments

Abstract

BACKGROUND: Gestational diabetes mellitus (GDM) is a risk factor for the development of type II diabetes and it causes maternal and child morbidity. Screening for diabetic retinopathy (DR) is important because patients who develop DR have no symptoms until macular edema and/or proliferative diabetic retinopathy (PDR) are already present. The aim of this study was to determine the early retinal findings of GDM.

MATERIAL AND METHODS: This study was conducted in a tertiary research center. We conducted a prospective cross-sectional study with 3 groups: Group 1 consisted of 36 pregnant women with GDM, Group 2 consisted of 24 healthy pregnant women, and Group 3 consisted of 38 healthy non-pregnant women of reproductive age. Spectralis optical coherence tomography (OCT) was used for the assessment. Macular, choroid, and retinal nerve fiber layer (RNFL) thicknesses were evaluated in patients with GDM and comparisons were made among pregnant women with GDM, healthy pregnant women, and healthy non-pregnant women for these parameters.

RESULTS: The nasal part of the RNFL was significantly thinner in the GDM group than in the healthy pregnant group. None of the patients had retinopathy or macular edema at the time of examination.

CONCLUSIONS: Decreased nasal part of RNFL thickness may be the first retinal change in patients with GDM. Our study suggests that OCT should be performed for the patients with GDM for detection of early retinal changes associated with GDM.

Keywords: Case-Control Studies, Choroid - pathology, Cross-Sectional Studies, Diabetes, Gestational - pathology, Diabetic Retinopathy - pathology, Macular Edema - pathology, Nerve Fibers - pathology, Optic Disk - pathology, Pregnancy, Prospective Studies, Retinal Degeneration - pathology, Tomography, Optical Coherence - methods, Visual Acuity

Background

Gestational diabetes mellitus (GDM) is a risk factor for the development of type II diabetes and is responsible for both maternal and child morbidity. Placental secretion of diabetogenic hormones, including growth hormone, corticotropin-releasing hormone, placental lactogen, and progesterone, is mainly attributable to development of GDM. The prevalence of GDM reported in the literature ranges from 2% to 9% [1].

Screening for diabetic retinopathy (DR) is important because patients who develop DR have no symptoms until macular edema (ME) and/or proliferative diabetic retinopathy (PDR) are already present. Proliferative diabetic retinopathy and ME are major leading causes of blindness in the young population [2,3].

The American College of Obstetricians and Gynecologists (ACOG), the American Diabetes Association (ADA), and the Fifth International Workshop Conference on Gestational Diabetes [4–6] recommend long-term follow-up of women with GDM. However, reports in the literature present no consistent guidelines about when GDM screening should begin. Professional organizations recommend that diabetes screening for women with GDM should occur around the time of the first postpartum visit [7–9], whereas the ADA recommends screening at 6–12 weeks after delivery.

There is no data about early retinal findings of GDM. To the best of our knowledge, this is the first published study comparing macular and peripapillary nerve fiber layer (RNFL) and choroidal thickness changes among GDM patients, healthy pregnant women, and healthy non-pregnant women. Optical coherence tomography (OCT) is a non-invasive imaging technique that can measure retinal layers with a resolution of 3–10 microns [10].

The present study aimed to examine macular, peripapillary RNFL and choroidal thickness changes in patients with GDM and to compare them to healthy pregnant and non-pregnant subjects.

Material and Methods

STATISTICS ANALYSIS:

The Kolmogorov-Smirnov test was used and histogram and q-q plots were examined to assess the data normality. The Levene test was used to assess the variance homogeneity. A 2-sided independent samples t test and 1-way analysis of variance (ANOVA) was applied to compare the differences between continuous variables. Welch test was applied when the homogeneity of variance assumption was violated. Tukey and Tamhane’s T2 tests were applied for multiple comparisons. Values are expressed as mean ± standard deviation. p<0.05 was considered as statistically significant.

Results

Mean age of the healthy non-pregnant group was 31.87±7.76, mean age of healthy pregnant group was 27.72±5.12 and mean age of GDM group was 32.51±4.88. GDM group was significantly older than healthy pregnant group.

The results of macular and choroidal thickness, macular volume, and peripapillary RNFL thickness analysis are shown in Tables 1–3, respectively. Macular central subfield and foveal center thickness were significantly thinner and choroidal thickness was significantly thicker in the healthy pregnant and GDM groups (p<0.001) (Table 1). However, there was no significant difference between the GDM group and the healthy pregnant group (Tables 1, 2). The nasal part of the RNFL was significantly thinner in the GDM group than the healthy pregnant group (Table 3). None of the patients had retinopathy at the time of examination.

Discussion

One of the most metabolically active organs in the body, the retina is particularly susceptible to substrate imbalance or ischemia [12]. Retinal pericytes and microvascular endothelial cells are lost at a very early stage of diabetes [13]. Proliferative diabetic retinopathy is a major complication of diabetes, which carries a high risk of visual loss [14]. Pregnancy is responsible for the worsening of PDR in women with pregestational type I or II DM [15]. Previous studies have shown that the prevalence of DR is 57–62% at the first examination in pregnancy with type I DM and is 17–28% in the type II DM. The Diabetes Control and Complications Trial (DCCT) and Research Group and the Diabetes in Early Pregnancy (DIEP) studies found the progression of retinopathy in pregnancy to range from 8% to 70% [16].

The literature is not clear on when GDM screening should begin. However, professional organizations recommend that diabetes screening for women with GDM should occur around the time of the first postpartum visit [7,8]. The ADA recommends screening at 6–12 weeks after delivery [9]. There is limited data on this issue and to the best of our knowledge this is the first study on GDM and the retina with OCT. The OCT technique can objectively and quantitatively assess macular and RNFL thickness [10,17].

The present study revealed that macular central subfield and foveal center thickness were significantly thinner and choroidal thickness was significantly thicker in the healthy pregnant and GDM groups than in the healthy non-pregnant group (p<0.001), but there were no significant difference between the GDM group and the healthy pregnant group. Cankaya et al. determined that the mean macular central subfield value was 192 μm in non-pregnant healthy women, but Grover et al. reported that the mean macular central subfield value was 270.2 μm in healthy subjects [18,19]. In our study macular thickness values in healthy non-pregnant subjects were similar to that reported by Grovers.

The novel finding of this study was that thickness of RNFL, especially the nasal part, significantly decreased in patients with GDM. Thus, the decreased nasal part of RNFL thickness may be the first change in patients with GDM. Timing of scanning for GDM is very important because screening allows detection of retinopathy in the early and non-proliferative stage. GDM patients have more severe insulin resistance compared to euglycemic pregnant women [20,21]. At this stage, improving glycemic control can reverse non-proliferative changes and prevent progression [22]. It was reported that choroidal thickness was reduced in diabetic eyes and that the nasal quadrant was the most affected area [23]. Nasal quadrant choroid layer supplies blood to this area; therefore, we are of the opinion that this situation may explain why the nasal part of RNFL was significantly reduced in patients with GDM. Kida et al. examined optic nerve head (ONH) blood circulation during 75-gr OGTT. They concluded that ONH circulation decreased in the abnormal glucose tolerance group, attributed partly to the increased endothelin-1 [24]. In a similar study, authors investigated the microcirculation and progression of macular edema [25]. It is pointed out that the reduction of perifoveal capillary blood flow velocity may occur before the increase of retinal thickness at the central fovea in the diabetic patients. In contrast to Sakata and Vujosevic, it is claimed that pregnancy has no long-term effect on future progression. The adverse effect of pregnancy on the retinal microvasculature is relatively transient, with risk of progression to PDR being high only within the first 8 weeks after delivery. Increased risk may persist into the first year postpartum, but eventually diminishes [14].

This situation has been investigated at the molecular level. Yamagishi found that advanced glycation end-product-induced endothelial cell damage is inhibited by pigment epithelium-derived growth factor (PEDF), which possesses antioxidative, anti-inflammatory, and antiatherogenic properties in both cell culture and animal models [26]. On the other hand, PEDF is accepted as a negative regulator of vascular endothelial growth factor (VEGF) [27]. A plausible explanation and interpretation of these studies [23–27] is that high glucose level may lead to increased PEDF and ET-1 levels. Then, as a result of increased PEDF and ET-1 levels, VEGF begins to decrease. This situation results in decreased choroid thickness, especially in the nasal quadrant. Deterioration of blood supply to nerves may lead to thinner RNFL in patients with GDM.

Conclusions

The decreased nasal part of RNFL thickness may be the first retinal change in patients with GDM. Our study suggests that OCT should be performed for patients with GDM for detection of early retinal changes associated with GDM. The main question now is whether nasal value of RNFL can show us DR occurrence. A large-scale study with more participants is needed.

References

1. Correa PJ, Vargas JF, Sen S, Illanes SE, Prediction of gestational diabetes early in pregnancy: targeting the long-term complications: Gynecol Obstet Invest, 2014; 77; 145-49, pmid: 24401480

2. Stalnikiewicz L, Floriot M, Guerci B, Anqioi K, Progression of diabetic retinopathy during pregnancy: a retrospective analysis of a series of 77 consecutive patients: J Fr Ophtalmol, 2010; 33; 481-86, pmid: 20674081

3. Vestgaard M, Ringholm L, Laugesen CS, Pregnancy-induced sight-threatening diabetic retinopathy in women with type 1 diabetes: Diabet Med, 2010; 27; 431-35, pmid: 20536515

4. Committee on Obstetric Practice, ACOG Committee Opinion No. 435: Postpartum screening for abnormal glucose tolerance in women who had gestational diabetes mellitus: Obstet Gynecol, 2009; 113; 1419-21, pmid: 19461459

5. Ferrara A, Weiss NS, Hedderson MM, Pregnancy plasma glucose levels exceeding the American Diabetes Association thresholds, but below the National Diabetes Data Group thresholds for gestational diabetes mellitus, are related to the risk of neonatal macrosomia, hypoglycaemia and hyperbilirubinaemia: Diabetologia, 2007; 50; 298-306, pmid: 17103140

6. Metzger BE, Gabbe SG, Persson BInternational Association of Diabetes and Pregnancy Study Groups Consensus Panel, International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia inpregnancy: Diabetes Care, 2010; 33; 676-82, pmid: 20190296

7. Cosson E, Valensi P, Carbillon L, Screening for dysglycaemia during pregnancy: Proposals conciliating International Association of Diabetes and Pregnancy Study Group (IADPSG) and US National Institutes of Health(NIH) panels: Diabetes Metab, 2014 pii: S1262-3636(14)00133-5

8. Wei Y, Yang H, Zhu W, International Association of Diabetes and Pregnancy Study Group criteria is suitable for gestational diabetes mellitus diagnosis: further evidence from China: Chin Med J (Engl), 2014; 127; 3553-56, pmid: 25316228

9. Buchanan TA, Page KA, Approach to the patient with gestational diabetes after delivery: J Clin Endocrinol Metab, 2011; 96; 3592-98, pmid: 22143829

10. Menke MN, Dabov S, Knecht P, Sturm V, Reproducibility of retinal thickness measurements in healthy subjects using spectralis optical coherence tomography: Am J Ophthalmol, 2009; 147; 467-72, pmid: 19026403

11. Shao L, Wang Y, Xu J, Subfoveal choroidal thickness of Chinese aged over 50 years and patients with diabetes mellitus and glaucoma: Zhonghua Yan Ke Za Zhi, 2014; 50; 414-20, pmid: 25241973

12. F Stitt AW, O’Neill CL, O’Doherty MT, Vascular stem cells and ischaemic retinopathies: Prog Retin Eye Res, 2011; 30; 149-66, pmid: 21352947

13. Valdez CN, Arboleda-Velasquez JF, Amarnani DS, Retinal microangiopathy in a mouse model of inducible mural cell loss: Am J Pathol, 2014; 184; 2618-26, pmid: 25092275

14. Errera MH, Kohly RP, da Cruz L, Pregnancy-associated retinal diseases and their management: Surv Ophthalmol, 2013; 58; 127-42, pmid: 23410822

15. Rasmussen KL, Laugesen CS, Ringholm L, Progression of diabetic retinopathy during pregnancy in women with type 2 diabetes: Diabetologia, 2010; 53; 1076-83, pmid: 20225131

16. Buchanan TA, Kathleen A, Approach to the patient with gestational diabetes after delivery: J Clin Endocrinol Metab, 2011; 96; 3592-98, pmid: 22143829

17. Liu MM, Wolfson Y, Bressler SB, Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema: Invest Ophthalmol Vis Sci, 2014; 55; 1370-77, pmid: 24526445

18. Grover S, Murthy RK, Brar VS, Chalam KV, Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis): Am J Ophthalmol, 2009; 148; 266-71, pmid: 19427616

19. Cankaya C, Bozkurt M, Ulutas O, Total macular volume and foveal retinal thickness alterations in healthy pregnant women: Semin Ophthalmol, 2013; 28; 103-11, pmid: 23448567

20. Li YY, Xiao R, Li CP, Increased plasma levels of FABP4 and PTEN Is associated with more severe insulin resistance in women with gestational diabetes mellitus: Med Sci Monit, 2015; 21; 426-31, pmid: 25659997

21. Stein RG, Meinusch M, Diessner J, Amniotic fluid insulin and C-peptide as predictive markers for fetal macrosomia, birth injuries, and delivery complications?: Med Sci Monit, 2014; 20; 54-58, pmid: 24423633

22. Zoungas S, Chalmers J, Neal BADVANCE-ON Collaborative Group, Follow-up of blood-pressure lowering and glucose control in type 2 diabetes: N Engl J Med, 2014; 371; 1392-406, pmid: 25234206

23. Vujosevic S, Martini F, Cavarzeran F, Macular and peripapillary choroidal thickness in diabetic patients: Retina, 2012; 32; 1781-90, pmid: 22869022

24. Kida T, Sugiyama T, Oku H, Plasma endothelin-1 levels depress optic nerve head circulation detected during the glucose tolerance test: Graefes Arch Clin Exp Ophthalmol, 2007; 245; 1289-93, pmid: 17226022

25. Sakata K, Funatsu H, Harino S, Relationship between macular microcirculation and progression of diabetic macular edema: Ophthalmology, 2006; 113; 1385-91, pmid: 16877077

26. Yamagishi S, Matsui T, Nakamura K, Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders: Curr Pharm Des, 2009; 15; 1027-33, pmid: 19275665

27. Dace DS, Khan AA, Kelly J, Apte RS, Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development: PLoS ONE, 2008; 3; e3381, pmid: 18852882

In Press

Clinical Research  

Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...

Med Sci Monit In Press; DOI: 10.12659/MSM.951027  

Clinical Research  

Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...

Med Sci Monit In Press; DOI: 10.12659/MSM.950516  

Review article  

Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A Review

Med Sci Monit In Press; DOI: 10.12659/MSM.951283  

Clinical Research  

Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 Adults

Med Sci Monit In Press; DOI: 10.12659/MSM.950938  

Most Viewed Current Articles

17 Jan 2024 : Review article   10,187,196

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

13 Nov 2021 : Clinical Research   3,708,487

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

0:00

14 Dec 2022 : Clinical Research   2,341,643

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research   706,524

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750